Xiaoxue Xie1, Steven H Lin2, James W Welsh2, Xiong Wei2, Hekun Jin1, Radhe Mohan3, Zhongxing Liao2, Ting Xu4. 1. Hunan Key Laboratory of Translational Radiation Oncology, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China. 2. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. 3. Department of Radiation Physics, The University of Texas MD Anderson Cancer Center, Houston, USA. 4. Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, USA. Electronic address: TXu@mdanderson.org.
Abstract
BACKGROUND & PURPOSE: We investigated clinical and genetic factors associated with severe radiation-induced lymphopenia (RIL) in a randomized clinical trial of photon vs. proton radiation, with chemotherapy, for non-small cell lung cancer. METHODS: XRCC1 rs25487 was genotyped in lymphocytes from serial peripheral blood samples. Severe RIL was defined as absolute lymphocyte count (ALC) < 0.3 × 109 cells/L. Univariate and multivariate analyses were used to identify independent risk factors, which were then used to group patients for risk of severe RIL. RESULTS: Univariate analysis of the 178 patients in this analysis showed that older age, larger tumors, higher lung V5 and mean lung dose, and higher heart V5 and mean heart dose were associated with severe RIL during treatment (P < 0.05). The XRCC1 rs25487 AA genotype was also associated with increased risk of severe RIL during treatment (AA vs. others: hazard ratio [HR] = 1.665, 95% confidence interval [CI] 1.089-2.500, P = 0.018). Multivariate analyses showed that older age (HR = 1.031, 95% CI 1.009-1.054, P = 0.005), lung V5 (HR = 1.039, 95% CI 1.023-1.055, P < 0.0001), and AA genotype (AA vs. others, HR = 1.768, 95% CI 1.165-2.684, P = 0.007) were independently associated with higher incidence of severe RIL. These three risk factors (age ≥ 56 years, lung V5 ≥ 51% and XRCC1 rs25487 AA) distinguished patients at different risk of developing severe RIL (P < 0.0001). CONCLUSIONS: Age, lung V5 and XRCC1 rs25487 AA were all linked with risk of severe RIL. Our predictive risk model may be helpful for identifying patients at high risk of severe RIL so that treatment can be modified.
BACKGROUND & PURPOSE: We investigated clinical and genetic factors associated with severe radiation-induced lymphopenia (RIL) in a randomized clinical trial of photon vs. proton radiation, with chemotherapy, for non-small cell lung cancer. METHODS: XRCC1 rs25487 was genotyped in lymphocytes from serial peripheral blood samples. Severe RIL was defined as absolute lymphocyte count (ALC) < 0.3 × 109 cells/L. Univariate and multivariate analyses were used to identify independent risk factors, which were then used to group patients for risk of severe RIL. RESULTS: Univariate analysis of the 178 patients in this analysis showed that older age, larger tumors, higher lung V5 and mean lung dose, and higher heart V5 and mean heart dose were associated with severe RIL during treatment (P < 0.05). The XRCC1 rs25487 AA genotype was also associated with increased risk of severe RIL during treatment (AA vs. others: hazard ratio [HR] = 1.665, 95% confidence interval [CI] 1.089-2.500, P = 0.018). Multivariate analyses showed that older age (HR = 1.031, 95% CI 1.009-1.054, P = 0.005), lung V5 (HR = 1.039, 95% CI 1.023-1.055, P < 0.0001), and AA genotype (AA vs. others, HR = 1.768, 95% CI 1.165-2.684, P = 0.007) were independently associated with higher incidence of severe RIL. These three risk factors (age ≥ 56 years, lung V5 ≥ 51% and XRCC1 rs25487 AA) distinguished patients at different risk of developing severe RIL (P < 0.0001). CONCLUSIONS: Age, lung V5 and XRCC1 rs25487 AA were all linked with risk of severe RIL. Our predictive risk model may be helpful for identifying patients at high risk of severe RIL so that treatment can be modified.
Authors: Jenny Chang-Claude; Odilia Popanda; Xiang-Lin Tan; Silke Kropp; Irmgard Helmbold; Dietrich von Fournier; Wulf Haase; Marie Luise Sautter-Bihl; Frederik Wenz; Peter Schmezer; Christine B Ambrosone Journal: Clin Cancer Res Date: 2005-07-01 Impact factor: 12.531
Authors: Awalpreet S Chadha; Guan Liu; Hsiang-Chun Chen; Prajnan Das; Bruce D Minsky; Usama Mahmood; Marc E Delclos; Yelin Suh; Gabriel O Sawakuchi; Sam Beddar; Matthew H Katz; Jason B Fleming; Milind M Javle; Gauri R Varadhachary; Robert A Wolff; Christopher H Crane; Xuemei Wang; Howard Thames; Sunil Krishnan Journal: Int J Radiat Oncol Biol Phys Date: 2016-11-08 Impact factor: 7.038
Authors: Zhongxing Liao; J Jack Lee; Ritsuko Komaki; Daniel R Gomez; Michael S O'Reilly; Frank V Fossella; George R Blumenschein; John V Heymach; Ara A Vaporciyan; Stephen G Swisher; Pamela K Allen; Noah Chan Choi; Thomas F DeLaney; Stephen M Hahn; James D Cox; Charles S Lu; Radhe Mohan Journal: J Clin Oncol Date: 2018-01-02 Impact factor: 44.544
Authors: Rajayogesh Davuluri; Wen Jiang; Penny Fang; Cai Xu; Ritsuko Komaki; Daniel R Gomez; James Welsh; James D Cox; Christopher H Crane; Charles C Hsu; Steven H Lin Journal: Int J Radiat Oncol Biol Phys Date: 2017-06-01 Impact factor: 7.038
Authors: Stuart A Grossman; Susannah Ellsworth; Jian Campian; Aaron T Wild; Joseph M Herman; Dan Laheru; Malcolm Brock; Ani Balmanoukian; Xiaobu Ye Journal: J Natl Compr Canc Netw Date: 2015-10 Impact factor: 11.908
Authors: Noel E Donlon; Maria Davern; Fiona O'Connell; Andrew Sheppard; Aisling Heeran; Anshul Bhardwaj; Christine Butler; Ravi Narayanasamy; Claire Donohoe; James J Phelan; Niamh Lynam-Lennon; Margaret R Dunne; Stephen Maher; Jacintha O'Sullivan; John V Reynolds; Joanne Lysaght Journal: World J Gastroenterol Date: 2022-06-07 Impact factor: 5.374
Authors: Gyu Sang Yoo; Jeong Il Yu; Sungkoo Cho; Youngyih Han; Yoonjin Oh; Do Hoon Lim; Hee Rim Nam; Ji-Won Lee; Ki-Woong Sung; Hyung Jin Shin Journal: Cancer Res Treat Date: 2021-10-15 Impact factor: 5.036
Authors: Wang Jing; Ting Xu; Lirong Wu; Pablo B Lopez; Clemens Grassberger; Susannah G Ellsworth; Radhe Mohan; Brian P Hobbs; George R Blumenschein; Janet Tu; Mehmet Altan; Percy Lee; Zhongxing Liao; Steven H Lin Journal: JTO Clin Res Rep Date: 2022-08-07